Discussion
Biliary tract cancers, biliary tract cancer, cancer, hepatobiliary cancers, deaths, primary hepatic malignancy
CANCER, BILIARY TRACT CANCER
Biliary tract cancers are detected late in many patients due to the lack of typical symptoms, have a high mortality and limited treatment options. Although considered being a rare type of cancer, BTC is the second most common primary hepatic malignancy, accounting for approximately 20% of deaths from hepatobiliary cancers, which cause 13% of the total cancer mortality worldwide [The usefulness of second-line therapy in patients refractory to gemcitabine-based first line chemotherapy in patients with BTC has long been the subject of controversy. Retrospective analyses have shown that patients in good general condition can benefit from cytotoxic chemotherapy in terms of overall survival and that combination therapies are more effective than single agents [Recently Liposomal irinotecan plus fluorouracil and leucovorin showed superior efficacy than fluorouracil and leucovorin in patients metastatic biliary tract cancer after progression on gemcitabine plus cisplatin [Trifluridine/tipiracil (FTD/TPI, trade name Lonsurf®) [